# Assessment of the Impact of antihypertensive Medications on vascular and renal outcomes in Chronic Kidney Disease (AIM-CKD)

> **NIH NIH R01** · CASE WESTERN RESERVE UNIVERSITY · 2024 · $671,516

## Abstract

Title: Assessment of the Impact of antihypertensive Medications on vascular and renal outcomes in Chronic
Kidney Disease (AIM-CKD)
Abstract
Chronic kidney disease (CKD), characterized by enduring damage to kidney function, poses a significant public
health concern, impacting around 15% of the adult population in the United States. CKD patients commonly
experience heightened adverse cardiovascular effects, which are associated with an elevated risk of mortality.
Foundational treatment strategies for slowing CKD progression involve blood pressure-lowering agents,
including renin-angiotensin system inhibitors and calcium channel blockers. These medications also exhibit
potential vasodilatory and anti-inflammatory properties. Nevertheless, the impact of these therapies on
cardiovascular disease outcomes in CKD patients is still in debate, and the tradeoff between risks and benefits
remains unclear due to limited clinical trials conducted thus far. To address this knowledge gap, we intend to
leverage data from two extensive studies: the Chronic Renal Insufficiency Cohort (CRIC) and the Systolic
Blood Pressure Intervention Trial (SPRINT). Our goal is to estimate and compare the effects of medications on
cardiovascular risks in CKD patients using novel and advanced causal inference methods. We recognize that
analyzing real-world data poses statistical challenges (e.g., time-varying treatment administration, competing
risk of death, treatment combination). However, these complexities cannot be directly addressed by current
causal inference techniques or may be addressed inefficiently. Our proposal focuses on time-to-event
outcomes, which accommodate detailed information, including the timing and duration of disease outcomes
that are crucial for understanding the natural progression of the disease and assessing the potential
effectiveness of interventions. Preliminary work has demonstrated the promise of our novel dynamic propensity
trajectory matching (DPTM) techniques, which guarantee further evaluation through theoretical and extensive
simulation studies conducted under various scenarios. Ultimately, we aim to develop user-friendly R software
packages and a Shiny app to facilitate the broader use of our research findings for the benefit of the public.

## Key facts

- **NIH application ID:** 10937430
- **Project number:** 1R01HL175410-01
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** MAHBOOB RAHMAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $671,516
- **Award type:** 1
- **Project period:** 2024-07-01 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10937430

## Citation

> US National Institutes of Health, RePORTER application 10937430, Assessment of the Impact of antihypertensive Medications on vascular and renal outcomes in Chronic Kidney Disease (AIM-CKD) (1R01HL175410-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10937430. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*